Aim. Studies based on pharmacy medication records have shown suboptimal adherence and persistence of osteoporosis treatment with oral bone sparing drugs (OBSD). Little is known about adherence and persistence of OBSD treatment in primary care. We assessed adherence and persistence of OBSD use of patients in general practices and identified associated factors. Methods. Using electronic medical records, adherence and persistence of newly prescribed treatment with OBSD in patients from 16 general practices was retrospectively assessed. The Medication Possession Ratio (MPR) was calculated as a proxy for adherence (MPR > 75%), persistence rates were estimated using survival analysis. Determinants of adherence and persistence using logistic regression and Cox regression analysis were assessed. Results. OBSD treatment was initiated in 957 patients. Seventy-five percent and 45% of the patients persisted OBSD treatment for one and five years, respectively. Being adherent in the first year decreased the risk of long-term non-persistence [hazard ratio (HR) 0.41; 95% confidence interval (CI) 0.3-0.57; P < 0.001]. Patients receiving the majority of their prescriptions by a specialist tended to be more non-persistent (HR 1.37; 96%; CI 0.96-1.94; P = 0.08). Adherence was 62.5% in the first year and 60.8% in the overall treatment period. Non-adherence was associated with the specialist being the main prescriber [odds ratio (OR) 3.76; 95% CI 2.43-5.82; P < 0.001] and younger age (<65 years, OR 1.44; 95% CI 1.01-2.08; P = 0.04). Conclusion. Older age of the patients and the GP prescribing the majority of medication were associated with better adherence and persistence. Good adherence in the first prescription year was associated with better persistence.
Introduction
Oral bone sparing drugs (OBSD), bisphosphonates in particular, are the first choice for the prevention and treatment of osteoporosis and patients with a high risk of fracture (1) . OBSD have been shown to reduce the number of fractures by 20-50% (2, 3) .To achieve fracture reduction, a treatment duration (i.e. persistence of prescribed treatmentof at least three to five years is recommended (1) .The treatment does not reduce fractures if the adherence (i.e. the extent to which patients take their medication as prescribed) is 50% or less and reaches its maximum effect from 75% onward) (3) . However, several studies, predominantly based on pharmacy medication record (PMR) and health insurance claim data, have shown that both adherence to and persistence of treatment with OBSD is sub-optimal (4, 5) . In recent studies in predominantly postmenopausal women using weekly dosed bisphosphonates, first year adherence rates were found to range from 58 to 67% (6, 7) , whereas first year persistence rates ranged from 28 to 63% (6) (7) (8) (9) (10) .
In the Netherlands where OBSD treatment is fully reimbursed, on the basis of PMR data one-year persistence rates were found to range from 43 to 68% (11) (12) (13) (14) (15) . Non-adherence and early discontinuation of OBSD treatment considerably reduce thebeneficial effect of treatment and increase both morbidity and the financial burden on the health care system (16, 17) .
In the Netherlands, OBSD are mainly used for the treatment of osteoporosis. Treatment is initiated both at the primary and secondary care level. In the latter setting, most patients are high-risk patients with advanced osteoporosis and complications and/or fractures, or have secondary osteoporosis (18, 19) . Main indications for the start of bone sparing drugs are prevalent vertebral fractures or the combination of decreased bone mineral density measured by DEXA (T < −2.5) and either several risk factors for fractures, recent non-vertebral fractures after 50 years of age with secondary osteoporosis being mainly treated in secondary care (18, 19) . Due to the lack of evidence of fracture reduction of bisphosphonates in pragmatic studies, the primary care guideline advices to be restrained in fracture prevention if no fractures have occurred and leaves room for patient considerations not to initiate treatment. Little is known about adherence to and persistence of treatment with OBSD prescribed in primary care and specific factors associated with adherence and persistence in this setting. Data from two studies on persistence of treatment in primary care showed first year persistence rates of 32-58% and 9-24% at five years (9, 20) . However, in these studies, adherence was not evaluated and determinants of persistence were not explored. The present study aimed to assess the adherence to and persistence of treatment of OBSD in patients of Dutch general practices. In addition, variables associated with (non)adherence and (non)persistence were also examined.
Material and Methods
The present study was a retrospective database analysis of a historic cohort in a general practice database containing electronic medical records (EMR) extractions. Primary outcomes of interest were adherence to and persistence of treatment with OBSD.
Source population
The Academic Network of General Practitioners (ANGP)database managed by the Department of General Practice and Elderly Care Medicine, VUmc, Amsterdam, contains anonymized EMR data of patients of 32 general practices (54 GPs) in the Amsterdam/Haarlem city area. All GPs in the ANGP are regularly trained in registration in EMRs. Medical data are coded according to the International Classification of Primary Care (ICPC) (21) . GPs receive feedback reports on an annual basis. Recently, a random sample of 25 contact registrations of each GP of the ANGP database analysed by two independent GPs showed that EMR data extractions were complete and correctly coded in 92.5% (range, 61.6-99.8%) and 80% (range, 77.7-96%) of cases (not yet published data). A numberof ANGP practices (n = 16) is linked to a regional pharmacy data network allowing their EMRs to be completed with dispensing data ensuring that all prescriptions from all physicians other than GPs, such as specialists, are also recorded in these EMRs. There were no specific fracture prevention programmes or special clinics for osteoporosis in any primary or secondary care setting in the region of the study during the period of data extraction (1 January 2003-31 December 2010).
Study population
In the present study, only data from linked practices was used. All patients who were newly prescribed OBSD [alendronate, etidronate, ibandronate, risedronate and strontium ranelate, (ATC codes M05BA, MO5BB, MO5BX or MO5BX53)] after April 2003 were included in the dataset (baseline data). However, since chronic medication is generally prescribed for a period of three months at a time in the Netherlands, study data extraction started six months earlier in order to ensure that only patients with a first time prescription were included. Each patient was followed from the index date (date of the first OBSD prescription) until the end of data collection (date of transfer out of practice, death, or 31 December 2010, whichever came first). Patients who were prescribed OBSD in a dosage usually prescribed for indications other than osteoporosis (e.g. malignancies and M. Paget) were excluded as well as those who had only received a single prescription or were dispensed OBSD once. Since it was impossible to verify whether treatment was started at all. Patients of the latter group were excluded in order to eliminate interference of non-adherence in the initiating phase of treatment, which differs from non-adherence as described later on in this manuscript.
Validation of prescription data
To ensure the validity of the linkage of pharmacy dispensing data to the EMR and consequently their extraction into the ANGP database, an EMR data sample was compared to the actual dispensing data of the pharmacies (PMR). From each practice, 10 patients who had been prescribed OBSD at least at two different occasions, were randomly selected and asked which pharmacies had dispensed their medication. The sample was stratified according to the main prescriber of OBSD (GP or specialist, each n = 5). Data on OBSD that were actually dispensed was obtained from the pharmacies that the patients had indicated.
Outcomes
'Persistence' was calculated by counting the number of days between the first and the last prescription for patients who were prescribed OBSD for a period of at least one year. If a patient restarted therapy after a prescription free period of one year, the subsequent initiation of treatment was excluded from the analysis. In this case, the date of the last prescription before the first gap was used to calculate persistence. Patients who were still prescribed OBSD at the end of follow-up were considered as 'still using medication'.
'Adherence' is commonly expressed by calculating the Medication Possession Ratio (MPR) (22) . The MPR was calculated by dividing the cumulative 'defined daily dose' (DDD) during each consecutive year of treatment by the number of days between the first and the last prescription or to the end of follow-up (22) . In calculating the MPR, the last prescription was excluded because due to uncertainty whether the medication was actually used and for how long. For patients of whom it was impossible to assess the end of treatment and who were still using OBSD at the end of the study period, the yearly and overall MPR were calculated until the last prescription. Adherence was treated as a dichotomous variable: MPR ≥75 indicating adherence and MPRs <75 indicating non-adherence.
Determinants
The following determinants were assessed at the start of follow-up: age, gender and presence of an ICPC fracture code (L72-L76) after the age of 50. The number of ICPC codes of chronic diseases as defined in the Dutch National Institute for Public Health and the Environment (RIVM) list (23) . The number of chronic medications used (3 or more prescriptions of the same drug in one year) and the total number of contacts with the GP were assessed in the first year after baseline. It was also assessed who (GP or specialist) had issued the initial OBSD prescription, and who wrote the majority of repeat prescriptions. For continuous determinants, a tertile distribution was used.
Statistical analysis
Descriptive statistics were used to address missing prescriptions in the ANGP database. For the validation analysis, the EMR data sample was compared with the PMR data by using 4 × 4-tables and the McNemar test. The validity of persistence was assessed by a t-test for repeated measures (IBM SPSS statistics v20).
Associations between adherence or persistence and the determinants were first tested univariate using multilevel mixed effects methods with the GP practice added as random effect using an independent co-variance structure (STATA v14.1). Variables with a P value ≤0.2 in the univariate analyses were combined into a multivariate analysis. A backward selection method was then utilized and stepwise variables with significance level of P >0.1 were excluded from the final model. Parametric survival analysis was used to evaluate associations between non-persistence (time of discontinuation of medication) and the determinants. Log Minus Log (LML)-plots were performed to test the proportional hazard assumption. For additional insight into longer term persistence (3 and 5 years, analysed as dichotomous variables), the association with first year and overall non-adherence (dichotomous; MPR < 75%) and other determinants was tested first univariate and then multivariate using logistic regression (IBM SPSS statistics v20).
Results

Baseline characteristics
The source population comprised of 61 663 patients in the 16 ANGP practices. Of these patients, 1678 were prescribed OBSD between April 2003 and January 2011. A total of 721 patients were excluded because the onset of the treatment could not be established (n = 458), because of primary non-adherence (n = 211) or because OBSD were used for other indications than osteoporosis (n = 52). After exclusion, 957 patients remained for further analysis. Their characteristics have been listed in Table 1 .
Validation of the prescription data
Of the 140 patients who were asked to give informed consent for the validation of prescribing with dispensing data, 89 consented. This resulted in 1237 prescriptions (83 664 DDD's). All GP prescriptions were dispensed by community pharmacies. No significant differences were found for adherence between the original and sample results. However, 11 out of 60 patients were persistent significantly longer than appearing from the EMR data (mean difference 0.49 years). There was also no significant difference in the number of missing prescriptions between GP or specialist as main prescriber.
Persistence Figure 1 shows a Kaplan-Meier plot of persistence over time. First year persistence was 75% whereas five-year persistence amounted to 45%. Median persistence was 1.5 years (Table 1) . Using LMLplots the proportional hazards assumptions were found to hold for all variables. The following variables were associated with overall persistence in the univariate analysis: age at start of treatment, treatment initiator, main prescriber and first year adherence (Table 2) . Multivariate analysis of the significant variables (Table 3) showed a strong association between being adherent in the first year of treatment and overall persistence (HR 0.41; 95% CI: 0.30-0.57). In the case that the majority of prescriptions were prescribed by a specialist, there was an elevated risk of non-persistence (HR 1.37; 95% CI: 0.96-1.94). This was confirmed by the additional analysis of those who were persistent for at least 3 years (Table 3) .
Adherence
In the first treatment year, 62.5% of the patients were adherent (MPR ≥ 75%). Overall adherence was 60.8% (Table 1) .
Variables in the univariate analysis that were associated with non-adherence in both the first year (data not shown) and overall (Table 1) were the specialist as the main prescriber and treatment initiator, being younger (≤65) at start of treatment and >11 Table 1 . Characteristics of the n = 957 oral bone sparing drugs (OBSD) using patients in the GP database in which the start could be determined and who received or filled at least two prescriptions consultations in the first treatment year. The final multivariate association model for first year and overall non-adherence are shown in Table 4 . The specialist as main prescriber was associated with an increased risk of overall non-adherence (OR 3.76; 95% CI 0.97-3.65) whereas higher age was associated with a decreased risk (OR 0.69; 95% CI 0.48-0.99.)
Discussion
About 60% of the patients who were newly prescribed OBSD were adherent (MPR ≥ 75%) during the first year of treatment. Having a GP as main prescriber and being older were factors associated with adherence. Median persistence amounted a year and a half and an estimated 45% of patients were persistent for five years; the minimum recommended treatment period for OBSD in the Netherlands. A specialist as main prescriber and being older increased the risk of non-persistence.
Persistence
First year persistence observed in the present study, 76%, was at the higher end of the range of previous findings. During our data collection period, weekly OBSD dosages were introduced. In our dataset, both daily and weekly dosages were prescribed throughout the data collection period. The weekly dosages positively may have influenced persistence (24) . By calculating the yearly MPR, even for participants who did not complete a full year of treatment, a time factor was incorporated into the measure of adherence. In order to generate statements about the association between adherence and persistence in the present study only patients who were persistent for at least one year (in the persistence analyses) were included. A first year MPR ≥75% was positively associated with overall persistence indicating that adherence and persistence are closely linked variables. A substantial number of patients continued their treatment beyond this period contrary to the Dutch GP Guidelines (18, 19) . These patients were probably never advised to stop using OBSD or constituted a specific subgroup of patients (e.g. corticosteroid users).
Adherence
In the present study, mean first year adherence of 62.5% fell within the range of previously reported data. We excluded 211 (12.6%) patients that discontinued treatment after a single prescription. Although commonly applied, the exclusion leads to a underestimation of non-adherence (22) . Reasons for not starting OBSD are thought to be different from secondary discontinuation, and not starting was therefore a reason for exclusion (25, 26) . The level of not starting OBSD found in the only study know to us is a little higher (29.5%) than our findings (26) .
Patients that were adherent in the first year of therapy had higher overall persistence in the following treatment years. Supporting patients with adherence and persistence in the first year of treatment and acting on these parameters might be beneficial. Being older was found to be a protective quality for non-adherence (during the first treatment year and in overall adherence (OR 0.70; 95% CI 0.49-1.00). Other studies obtained similar results (24, (27) (28) (29) . In contrast to other studies, an association between the number of chronic diseases, fractures, gender, co-medication was not observed in the present study (13, 15, 24, (27) (28) (29) (30) . This may be due to the sample size of the study, but also due to differences in types of co-morbidity considered, the method used to assess adherence (e.g. database versus self-reported), differences in coding, a difference in population with respect to the distribution of gender and the use of different cut-off values for co-medication tertiles. Of the patients that initiated OBSD, only 24.7% of the patients had an ICPC fracture code in their EMR. This is surprising, since fracture is one of the most important indications for OBSD in the GP guideline. The explanation might be that fractures are diagnosed and treated in secondary care and are not always coded in the EMR of the GP. Our study is the first study in which a medical specialist either as the prescriber of the majority of the medication (main prescriber) or as the initiator of treatment versus the GP was associated with an increased risk of non-adherence and persistence in both the first year of treatment as for a longer period of time. In line with our results, a recent Dutch study, using pharmacy dispensing data found that five years persistency of patient treated by a GP was higher (45%) than patient treated by a specialist (39%) (15) . In contrast, an older study found decreased odds for non-adherence when the specialist was the first prescriber (13) . However, these data were accumulated at a time that no GP guideline for the treatment of osteoporosis had been published yet. In a secondary care fracture prevention program in Australia, higher initiation of therapy was observed but no difference in adherence and persistence compared to non-specialist management (27) . A possible explanation for our finding is the restrain on bisphosphonate treatment in patients without fracture that is advocated in the Dutch primary care guide line. It has been shown that prior fracture is a positive determinant of OBSD persistence (28, 29) . Additional factors might be continuity of care or the emphasis on patient decision in treatment initiation in the GP guide line, but many other explanations are also possible. However, further study of this phenomenon might lead to interesting insight.
Strengths and limitations
A major strength of the present study is the long follow-up period that allowed to evaluate adherence and persistence over the recommended period of OBSD treatment in a large group of patients of several GP practices. As confirmed by the comparison of a sample of GP EMR database records with PMR data, information on prescriptions provided by the GP EMR database was sufficiently accurate to calculate adherence and persistence. However, some limitations have to be addressed as well. First, we studied the database of a GP registration network. It is possible that these GP's are not comparable to usual GP's. However, both age, gender and consultation frequency of the patients receiving OBSD in the database are comparable to what previously has been reported (15, 29, 30) . Another limitation is that adherence and persistence have been evaluated based on prescription data. Although it was confirmed that almost all GP prescriptions were filled by the pharmacies, a small portion of the OBSD dispensed by the pharmacies was not registered in the GP EMR, resulting in a small underestimation of persistence. It is also possible that patients have collected their medicines but forgot to take their drugs, skipped doses or interrupted medication use, which would lead to an overestimation of adherence and persistence rates. MPRs exceeding 100% were accepted. Although the MPR describes the actual adherence as precisely as possible, its use might result in a slight overestimation. It should also be noted that only patients who started treatment were included. Patients who intentionally did no start treatment represent another category (25, 26) .
Conclusion
Based on an analysis of GP EMR data, adherence to and persistence of treatment with OBSD in primary care patients were on the higher end of the ranges reported in studies at the secondary care or mixed level. Adherence and persistence rates were better in the case that the patients' GP rather than a medical specialist prescribed the OBSD. Since the differences between adherence and persistence of OBSD between primary and secondary care have hardly been reported before, this needs further study. Patients who are adherent (MPR ≥ 75%) during first treatment year have a better chance of being persistent. This suggests that patients with a low adherence in the months after the start of treatment might need additional support to fully obtain the beneficiary effect of OBSD treatment.
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